Abstract
More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/ oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCRrelated very complex neurodegenerative diseases, such as Parkinsons disease (PD), Alzheimers disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.
Keywords: Multivalent ligand, G-protein-coupled receptors (GPCRs), drug design and development, heterodimerization, Parkinson's disease, Alzheimer's disease, schizophrenia, drug abuse, drug target
Current Pharmaceutical Design
Title: Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors
Volume: 15 Issue: 6
Author(s): Zhili Liu, Jing Zhang and Ao Zhang
Affiliation:
Keywords: Multivalent ligand, G-protein-coupled receptors (GPCRs), drug design and development, heterodimerization, Parkinson's disease, Alzheimer's disease, schizophrenia, drug abuse, drug target
Abstract: More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/ oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCRrelated very complex neurodegenerative diseases, such as Parkinsons disease (PD), Alzheimers disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.
Export Options
About this article
Cite this article as:
Liu Zhili, Zhang Jing and Zhang Ao, Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors, Current Pharmaceutical Design 2009; 15 (6) . https://dx.doi.org/10.2174/138161209787315639
DOI https://dx.doi.org/10.2174/138161209787315639 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Nrf2-Heme Oxygenase-1 Axis after Intracerebral Hemorrhage
Current Pharmaceutical Design Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Looking for Organ Damages Due to Anabolic-androgenic Steroids (AAS): Is Oxidative Stress the Culprit?
Mini-Reviews in Organic Chemistry New Directions for Dementia
Current Neurovascular Research Targeting the Nicotinic Acetylcholine Receptors (nAChRs) in Astrocytes as a Potential Therapeutic Target in Parkinson’s Disease
Current Pharmaceutical Design Locked Nucleic Acid Holds Promise in the Treatment of Cancer
Current Pharmaceutical Design How Internet Technology Can Improve the Quality of Care for Substance Use Disorders
Current Drug Abuse Reviews Neuropsychiatric Symptoms and Functional Status in Alzheimer’s Disease and Vascular Dementia Patients
Current Alzheimer Research Fragile X Syndrome and Autism: Common Developmental Pathways?
Current Pediatric Reviews Narcolepsy in Adolescents: A Review and Three Case Reports
Adolescent Psychiatry 5-HT7 Receptor Ligands: Recent Developments and Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Lipid Nanoparticles for the Delivery of Biopharmaceuticals
Current Pharmaceutical Biotechnology Breakthrough Pain-Novel Analgesics
Current Clinical Pharmacology Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Histone Deacetylase 2 in the Mouse Hippocampus: Attenuation of Age- Related Increase by Caloric Restriction
Current Alzheimer Research Tissular Senescence and Modifications of Oral Ecosystem in the Elderly: Risk Factors for Mucosal Pathologies
Current Aging Science Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
Current Pharmaceutical Design Lifestyle and Health promotional Guidelines in Irritable Bowel Syndrome Patients from the Viewpoint of Persian Medicine
Current Traditional Medicine Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Potassium Channels as Targets for the Management of Pain
Central Nervous System Agents in Medicinal Chemistry